News | December 27, 2024
Mankind Pharma and Innovent Biologics join forces for cancer care with Sintilimab
Mankind Pharma will have exclusive rights to register, import, market, sell and distribute sintilimab in India
Mankind Pharma will have exclusive rights to register, import, market, sell and distribute sintilimab in India
The company will receive an upfront payment of Euro 100 million (Rs. 880 crores) for product development and site approval from European authorities
Afrezza, developed by MannKind Corporation in the USA, offers a needle-free, rapid-acting insulin option for diabetes management
Demonstrates vision gains with extended treatment intervals in retinal vein occlusion
The product will be marketed by Dr. Reddy's
HYMPAVZI’s approval is based on Phase 3 study results demonstrating non-inferiority and superiority compared to routine prophylaxis in eligible patients with hemophilia A or B without inhibitors
He did Master’s of Pharmacy (Pharmaceutical Technology, Formulations) from National Institute of Pharmaceutical Education and Research, Mohali and Bachelor of Pharmacy from Osmania University
The proceeds from its fresh issuance to the extent of Rs 107 crore will be utilized for funding the capital expenditure requirements
Strokes are affecting approximately 1.8 million people annually
Palivizumab (Synagis) is indicated for the prevention of serious lower respiratory tract disease requiring hospitalization caused by RSV in children at high risk for RSV disease
Subscribe To Our Newsletter & Stay Updated
